The story of Viagra presents a intricate picture for shareholders. While the initial launch generated massive profits, the lapse of its exclusive rights opened the floodgates to off-brand competitors, dramatically reducing revenue. This presents a particular challenge for pharmaceutical companies relying on similar blockbuster products, suggesting

The legacy of Viagra, and its creator copyright, presents a intriguing case study for investors. Initially a blockbuster drug, yielding billions in revenue , its patent expiration created a wave of generic competition , significantly eroding its dominance. While certain pharmaceutical companies may attempt to capitalize on related treatments , the